



Varuby

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
T/0015	Transfer of Marketing Authorisation	21/01/2019	11/03/2019	SmPC, Labelling and PL	
IB/0013	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	13/02/2019	n/a		
N/0014	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	10/01/2019	11/03/2019	PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



II/0007/G	This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	31/10/2018	11/03/2019	SmPC and PL	
IB/0011	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	26/09/2018	11/03/2019	SmPC	
IB/0009	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	21/09/2018	11/03/2019	SmPC	
PSUSA/10592 /201802	Periodic Safety Update EU Single assessment - rolapitant	01/09/2018	n/a		PRAC Recommendation - maintenance
IA/0010	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	08/08/2018	n/a		
IA/0006/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.f.1.e - Stability of FP - Change to an approved	23/04/2018	n/a		

	stability protocol				
PSUSA/10592 /201708	Periodic Safety Update EU Single assessment - rolapitant	12/04/2018	n/a		PRAC Recommendation - maintenance
IB/0005/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size	17/01/2018	n/a		
IB/0003	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	30/11/2017	n/a		
N/0002	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	02/10/2017	27/08/2018	PL	
IAIN/0001	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	01/09/2017	27/08/2018	Annex II and PL	

Medicinal product no longer authorised